Financial Performance Overview

Solara Active Pharma Sciences Limited reported mixed financial results for FY2025-26 with revenue growth but net losses. Consolidated revenue from operations reached ₹1,368.98 crores (7% YoY growth from ₹1,283.76 crores), while the company incurred a net loss of ₹7.41 crores attributable to owners, reversing from a profit of ₹0.54 crores in the previous year. Standalone performance showed similar trends with revenue of ₹1,375.14 crores and net loss of ₹7.24 crores.

Key Financial Metrics

Profitability: EBITDA stood at ₹191.54 crores (10% YoY growth), though the base business (excluding commodity ibuprofen) showed modest 6% revenue growth to ₹1,041 crores with flat EBITDA at ₹245 crores. The ibuprofen segment reported ₹334 crores revenue but incurred an EBITDA loss of ₹53 crores (76% increase in loss).

Balance Sheet: Total assets were ₹2,276.59 crores with equity of ₹1,255.44 crores. Borrowings reduced to ₹664.54 crores from ₹776.06 crores, while trade receivables increased to ₹438.87 crores. The company maintained cash and bank balances of ₹50.34 crores and made new investments in mutual funds totaling ₹3.00 crores.

Annual General Meeting and Corporate Governance

The Ninth Annual General Meeting is scheduled for September 18, 2026, to be held virtually. Key agenda items include:

  • Adoption of FY2025-26 standalone and consolidated financial statements
  • Re-appointment of Mr. Arun Kumar Pillai as Non-Executive Director
  • Ratification of cost auditor remuneration (₹4,75,000 plus expenses)
  • Approval of material related party transactions with Strides Pharma Science Limited up to ₹480 crores for sales, purchases, and reimbursements

Remote e-voting will be available from September 15-17, 2026, through CDSL/NSDL platforms. The board comprises 8 directors (2 Executive, 2 Non-Executive, 4 Independent) with all independent directors meeting statutory requirements.

Significant Developments and Challenges

Rights Issue: The company completed a rights issue offering 1,19,98,755 equity shares at ₹375 per share, raising ₹312.79 crore out of the planned ₹449.95 crore, with a second call notice issued for the balance.

Tax Litigation: Solara faces substantial income tax disputes totaling ₹161.92 crore for assessment years 2018-24, primarily concerning disallowance of depreciation on goodwill and product portfolio from demerger businesses. This creates potential unrecognized tax assets of ₹607.24 crore.

Audit Matters: Deloitte Haskins & Sells LLP issued an unmodified opinion but highlighted key audit matters regarding revenue recognition timing and impairment assessment of ₹364.90 crore goodwill, requiring significant judgment in cash flow projections and discount rates (21.35%).

ESG and Operational Metrics

The company disclosed comprehensive ESG data including:

  • Waste disposal: 606.12 metric tonnes (73.57 MT incinerated, 532.54 MT landfilled)
  • Water withdrawal: 255,066 kiloliters with intensity of 0.000019 KL/₹ turnover
  • GHG emissions: 27.15 metric tonnes of CO₂ per crore of turnover
  • Energy consumption: 69.9 kilo joules per rupee of turnover
  • MSME sourcing: 33% of total procurement
  • CSR investment: ₹0.76 crores focused on health, water, and education

Subsidiaries and Shareholding

Key subsidiaries include Synthix Global Pharma Solutions Limited (wholly-owned), Chemsynth Laboratories Private Limited (49%), and Shasun USA Inc (100%). The shareholding pattern shows Pronomz Ventures LLP increased promoter holding to 12.95% from 7.42%, while Authum Investment & Infrastructure emerged as a new 5.02% holder.

Outlook and Risks

Despite accumulated losses of ₹319.53 crore and net current liabilities, management believes the company remains a going concern based on expected working capital renewal, anticipated revenue growth, and cash inflows from operations. However, the ongoing tax litigation, commodity ibuprofen segment losses, and pending insurance claims for a November 2023 fire accident (₹61.12 crore damages) present significant challenges.